287 related articles for article (PubMed ID: 26427454)
1. Antisense Oligonucleotide Therapy for Inherited Retinal Dystrophies.
Gerard X; Garanto A; Rozet JM; Collin RW
Adv Exp Med Biol; 2016; 854():517-24. PubMed ID: 26427454
[TBL] [Abstract][Full Text] [Related]
2. Design and In Vitro Use of Antisense Oligonucleotides to Correct Pre-mRNA Splicing Defects in Inherited Retinal Dystrophies.
Garanto A; Collin RWJ
Methods Mol Biol; 2018; 1715():61-78. PubMed ID: 29188506
[TBL] [Abstract][Full Text] [Related]
3. Splicing-correcting therapeutic approaches for retinal dystrophies: where endogenous gene regulation and specificity matter.
Bacchi N; Casarosa S; Denti MA
Invest Ophthalmol Vis Sci; 2014 May; 55(5):3285-94. PubMed ID: 24867912
[TBL] [Abstract][Full Text] [Related]
4. RNA-Based Therapeutic Strategies for Inherited Retinal Dystrophies.
Garanto A
Adv Exp Med Biol; 2019; 1185():71-77. PubMed ID: 31884591
[TBL] [Abstract][Full Text] [Related]
5. Applications of antisense oligonucleotides for the treatment of inherited retinal diseases.
Collin RW; Garanto A
Curr Opin Ophthalmol; 2017 May; 28(3):260-266. PubMed ID: 28151748
[TBL] [Abstract][Full Text] [Related]
6. Generation of Humanized Zebrafish Models for the In Vivo Assessment of Antisense Oligonucleotide-Based Splice Modulation Therapies.
Schellens R; de Vrieze E; Slijkerman R; Kremer H; van Wijk E
Methods Mol Biol; 2022; 2434():281-299. PubMed ID: 35213025
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy in Retinal Dystrophies.
Ziccardi L; Cordeddu V; Gaddini L; Matteucci A; Parravano M; Malchiodi-Albedi F; Varano M
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739639
[TBL] [Abstract][Full Text] [Related]
8. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
9. Splicing modulation mediated by small nuclear RNAs as therapeutic approaches for muscular dystrophies.
Benchaouir R; Goyenvalle A
Curr Gene Ther; 2012 Jun; 12(3):179-91. PubMed ID: 22515846
[TBL] [Abstract][Full Text] [Related]
10. Antisense Oligonucleotide-Based Splice Correction of a Deep-Intronic Mutation in CHM Underlying Choroideremia.
Garanto A; van der Velde-Visser SD; Cremers FPM; Collin RWJ
Adv Exp Med Biol; 2018; 1074():83-89. PubMed ID: 29721931
[TBL] [Abstract][Full Text] [Related]
11. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
12. AON-Mediated Exon Skipping to Bypass Protein Truncation in Retinal Dystrophies Due to the Recurrent
Barny I; Perrault I; Michel C; Goudin N; Defoort-Dhellemmes S; Ghazi I; Kaplan J; Rozet JM; Gerard X
Genes (Basel); 2019 May; 10(5):. PubMed ID: 31091803
[TBL] [Abstract][Full Text] [Related]
13. The pros and cons of vertebrate animal models for functional and therapeutic research on inherited retinal dystrophies.
Slijkerman RW; Song F; Astuti GD; Huynen MA; van Wijk E; Stieger K; Collin RW
Prog Retin Eye Res; 2015 Sep; 48():137-59. PubMed ID: 25936606
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery.
Garanto A; Chung DC; Duijkers L; Corral-Serrano JC; Messchaert M; Xiao R; Bennett J; Vandenberghe LH; Collin RW
Hum Mol Genet; 2016 Jun; 25(12):2552-2563. PubMed ID: 27106101
[TBL] [Abstract][Full Text] [Related]
15. Antisense mediated splicing modulation for inherited metabolic diseases: challenges for delivery.
Pérez B; Vilageliu L; Grinberg D; Desviat LR
Nucleic Acid Ther; 2014 Feb; 24(1):48-56. PubMed ID: 24506780
[TBL] [Abstract][Full Text] [Related]
16. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Touznik A; Lee JJ; Yokota T
Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotide-mediated exon skipping of CHRNA1 pre-mRNA as potential therapy for Congenital Myasthenic Syndromes.
Tei S; Ishii HT; Mitsuhashi H; Ishiura S
Biochem Biophys Res Commun; 2015 Jun; 461(3):481-6. PubMed ID: 25888793
[TBL] [Abstract][Full Text] [Related]
18. Antisense Oligonucleotide Design and Evaluation of Splice-Modulating Properties Using Cell-Based Assays.
Slijkerman R; Kremer H; van Wijk E
Methods Mol Biol; 2018; 1828():519-530. PubMed ID: 30171565
[TBL] [Abstract][Full Text] [Related]
19. Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.
Aartsma-Rus A; Houlleberghs H; van Deutekom JC; van Ommen GJ; 't Hoen PA
Oligonucleotides; 2010 Apr; 20(2):69-77. PubMed ID: 20377429
[TBL] [Abstract][Full Text] [Related]
20. Translational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations.
Nagel-Wolfrum K; Möller F; Penner I; Wolfrum U
Vis Neurosci; 2014 Sep; 31(4-5):309-16. PubMed ID: 24912600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
